Cori, disease
|
(Forbes disease, glycogen storage disease type III)
Prevalence: 1/100.000. Hepatic glycogen storage disease (type III). Autosomal recessive transmission of mutations of the AGL gene (locus 1p21) resulting in deficiency in amylo1-6-glucosidase (debranching enzyme) preventing the complete degradation of glycogen into glucose: the result is a tendency to hypoglycemia and an accumulation of partially degraded glycogen in the liver and muscle cells. Variable clinical expression: in some cases only the liver or the muscles are affected.
Two clinical forms:
- form A: with liver and muscle involvement
- form B: hepatic involvement only.
The accumulation of dextrin in the liver causes hepatomegaly with hepatic fibrosis and sometimes the apparition of cirrhosis or adenomas. Sometimes a late hypertrophic obstructive cardiomyopathy (after the age of 30 years). Obesity is a frequent consequence of the diet (frequent meals). Muscle function: sometimes hypotonia in childhood; adulthood: progressive muscular atrophy, starting in the proximal areas, (high CPK levels when the muscle involvement becomes symptomatic.
Anesthetic implications:
- short fasting time or infusion of a glucose-containg electrolytic solution from the onset of the fasting period to avoid hypoglycemia
- difficult peripheral venous access
- sometimes macroglossia
- monitoring of blood glucose levels and muscle function
- avoid succinylcholine in case of muscle injury (risk of rhabdomyolysis ?)
- too frequent inflation of the BP cuff may cause local muscle cramps; use of a surgical tourniquet is best avoided
References :
- Mohart D, Russo P, Tobias JD.
Perioperative management of a child with glycogen storage disease type III undergoing cardiopulmonary bypass and repair of an atrial septal defect.
Pediatr Anesth 2002; 12: 649-54.
- Bolton SD, Clark VA, Norman JE.
Multidisciplinary management of an obstetric patient with glycogen storage disease type 3.
Int J Obstetr Anaesth 2011; 20: 86-9.
Updated: September 2019